🇺🇸 FDA
Pipeline program

AZD6244

D1532C00067

Phase 1 small_molecule completed

Quick answer

AZD6244 for Neoplasms, is a Phase 1 program (small_molecule) at AstraZeneca with 1 ClinicalTrials.gov record(s).

Program details

Company
AstraZeneca
Indication
Neoplasms,
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials